COVID-19, and more rarely the mRNA-based COVID-19 vaccine, can lead to inflammation of heart tissue in some individuals. A ...

Researchers at MIT have unveiled a way to temporarily reboot aging immune systems, using a targeted mRNA therapy that turns ...

The era of CureVac as an independent, publicly traded company has drawn to a close. BioNTech SE has successfully completed ...

By recycling the gases passing through a pyrolysis reactor, researchers have demonstrated a more efficient way to convert ...

As the immune system weakens with age, researchers have found a way to temporarily boost its function by reprogramming liver cells to support T-cell development.

The independent journey of CureVac as a publicly traded company has reached its conclusion. Following the expiration of the acceptance period, BioNTech has s ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Old mice experienced "rejuvenation" after receiving this injection. It is an injectable treatment utilizing ribonucleic acid ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

New data highlight liver-encoded delivery of immune modulators as a strategy to mitigate age-related immune dysfunction.